Exclusive: Genmab's CEO touts M&A potential as it inks first partnership outside cancer
Slowly and steadily, the Danish antibody specialist Genmab has grown into a $27 billion market cap powerhouse driven by cancer research.
Now, Genmab is making moves beyond oncology, announcing Monday a multi-year research deal with the Dutch drugmaker argenx to enter the massive immunology and inflammation market, Genmab CEO Jan van de Winkel told Endpoints News.
The companies will evenly split expenses and potential upside and start researching two undisclosed targets in cancer and immunology, though it could grow to more targets over time, van de Winkel said. Other collaborations with BioNTech and J&J’s Janssen have followed such trajectories.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.